Rebbaa, AbdelhadiPatil, GhanshyamSudha, ThangiralaMousa, Shaker A.2023-05-262023-05-262013-05Rebbaa, A. vd. (2013). “OT-404, multi-targeted anti-cancer agent affecting tumor proliferation, chemo-resistance, and angiogenesis”. Cancer Letters, 332(1), 55-62.0304-38351872-7980https://doi.org/10.1016/j.canlet.2013.01.016http://hdl.handle.net/11452/32804There is a need for a comprehensive anti-cancer strategy that simultaneously targets abnormal proliferation, angiogenesis rates, and development of chemotherapy resistance. We have identified a small molecule, OT-404, that effectively inhibited proliferation and angiogenesis of either chemo-sensitive or resistant human cancer cells and enhanced cancer cell sensitivity to different chemotherapy. In vivo studies of human tumor xenografts in nude mice showed that OT-404, used alone or encapsulated into nanoparticles, inhibited the growth of doxorubicin-resistant breast cancer MCF-7 by more than 80%, and by 95% when combined with doxorubicin. These findings provide evidence for the potential of OT-404 in cancer management.eninfo:eu-repo/semantics/closedAccessOncologyAngiogenesisChemo-resistanceNanoparticlesOT-404Hormone-releasing-hormoneEndothelial growth-factorThyroid-hormoneProngiogenic actionKinase inhibitorTyrosine kinaseDown-regülationCancer-therapyPhase-IIIn-vivoMus musculusAngiogenesis inhibitorsAnimalsAntineoplastic combined chemotherapy protocolsBreast neoplasmsCell proliferationChemistry, pharmaceuticalDose-response relationship, drugDoxorubicinDrug resistance, neoplasmFemaleHumansMaleMCF-7 cellsMiceMice, inbred C57BLMice, nudeNanocapsulesNeovascularization, physiologicTime factorsTumor burdenU937 cellsXenograft model antitumor assaysArticle0003167755000082-s2.0-848752553355562332123348692OncologyHsp90 Inhibitor; Ganetespib; TanespimycinAntineoplastic agentDoxorubicinEtoposideFibroblast growth factor 2NanoparticleOt 404Unclassified drugAnimal cellAnimal experimentAntineoplastic activityArticleBreast cancerCancer cellCancer growthCarcinogenesisControlled studyDrug efficacyDrug mechanismDrug targetingHumanHuman cellIn vivo studyMaleMouseNonhumanPriority journalTumor growthTumor volumeTumor xenograft